A Phase 1, Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Determine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Orally Administered Sotagliflozin in Healthy Chinese Subjects
Latest Information Update: 04 Sep 2019
At a glance
- Drugs Sotagliflozin (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions
- Sponsors Sanofi
Most Recent Events
- 26 Aug 2019 Status changed from recruiting to completed.
- 25 Apr 2019 Status changed from not yet recruiting to recruiting.
- 11 Apr 2019 New trial record